ASCO Coronavirus Resources

As the nation continues to respond to the coronavirus (COVID-19) pandemic, ASCO is committed to providing information and resources to its members and the larger oncology community to help ensure that individuals with cancer receive high-quality care.

ASCO's COVID-19 Road to Recovery Report

This ASCO report outlines recommendations for the cancer community’s recovery from the pandemic with an emphasis on accessible and equitable cancer care and research.

For information on COVID-19 vaccination, please refer to the US Centers for Disease Control.

ASCO and Conquer Cancer would like to thank the below donors for generously funding The COVID Impacts Cancer Fund.

Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Deciphera Pharmaceuticals, LLC
EMD Serono Inc.
Exelixis, Inc.
Genentech BioOncology TM
Gilead Sciences, Inc.
Incyte Corporation
Janssen Pharmaceutical Companies of Johnson & Johnson
Melanoma Research Foundation
Merck & Co., Inc.
Natera, Inc.
Nebraska Oncology Society
Novartis Oncology
Pfizer Oncology
Sanofi Genzyme
SeaGen Inc.
​TAIHO Oncology, Inc.
Takeda Oncology

Random Quote

"As medical professionals and as a Society, we must all continue to evolve and transform cancer care and research with each new discovery."
Julie M. Vose, MD, MBA, FASCO
ASCO President, 2015-16